{'fraction_non_alphanumeric': 0.02987012987012987, 'fraction_numerical': 0.007792207792207792, 'mean_word_length': 5.945945945945946, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Adenovirus‐mediated delivery of Factor H attenuates complement C3 induced pathology in the murine retina: a potential gene therapy for age‐related macular degeneration

Age‐related macular degeneration (AMD) is the most common cause of blindness in the elderly, with no therapy available for 90% of patients. Recent genetic evidence implicates activation of complement in the pathogenesis of AMD. We have recently discovered that adenovirus (Ad)‐mediated expression of complement component C3 (AdCMVC3) in the murine retina recapitulates many of the pathological features found in human AMD. In the present study, utilizing a gene therapy approach, we examine whether Ad‐mediated expression of complement Factor H (AdCAGfH) attenuates AdCMVC3‐mediated retinal pathology.